Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
50%(1 trials)

Phase Distribution

Ph phase_3
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 3Large-scale testing
1(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(2)

Detailed Status

Completed2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (66.7%)
Phase 31 (33.3%)

Trials by Status

recruiting133%
completed267%

Recent Activity

1 active trials
Showing 3 of 3
recruitingphase_3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

NCT06072612
completedphase_1

Combination Study of SV-BR-1-GM With Retifanlimab

NCT03328026
completedphase_1

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

NCT03066947

Clinical Trials (3)

Showing 3 of 3 trials
NCT06072612Phase 3

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Recruiting
NCT03328026Phase 1

Combination Study of SV-BR-1-GM With Retifanlimab

Completed
NCT03066947Phase 1

SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer

Completed

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3